1. CH Fanta. Asthma. N Engl J Med 2009; 360:1002.
2. PM O'Byrne. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol 2011; 128:257.
3. JP Parsons et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187:1016.
4. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report (EPR) 3. Guidelines for the diagnosis and management of asthma. Full Report 2007. Available at www.nhlbi.nih.gov/guidelines/asthma/index.htm. Accessed June 13, 2013.
5. MA Rank et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131:724.
6. WJ Calhoun et al. Comparison of physician-, biomarker-, and symptombased strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012; 308:987.
7. HW Kelly. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009; 43:519.
8. HW Kelly et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904.
9. PM O'Byrne et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183:589.
10. E Bateman et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149:33.
11. RF Lemanske, Jr et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.
12. AW McMahon et al. Age and risks of FDA-approved long-acting ßadrenergic receptor agonists. Pediatrics 2011; 128:e1147.
13. JL Brozek et al. Long-acting beta2 agonist step-off in patients with controlled asthma. Arch Intern Med 2012; 172:1365.
14. BA Chowdhury et al. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011; 364:2473.
15. D Price et al. Leukotriene antagonists as first-line or add-on asthmacontroller therapy. N Engl J Med 2011; 364:1695.
16. SP Peters et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363:1715.
17. HA Kerstjens et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128:308.
18. HA Kerstjens et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367:1198.
19. GJ Rodrigo et al. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28.
20. NA Hanania et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573.
21. WW Busse et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005.
22. L Cox et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128:210.
23. MA Calderón et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30.
24. Bronchial thermoplasty for asthma. Med Lett Dugs Ther 2010; 52:65.
25. FM Ducharme et al. Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control. Am J Respir Crit Care Med 2011; 183:195.
26. J Oborne et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009; 180:598.
27. SC Lazarus. Emergency treatment of asthma. N Engl J Med 2010; 363:755.
28. V Bougault et al. Airway hyperresponsiveness in elite swimmers: is it a transient phenomenon? J Allergy Clin Immunol 2011; 127:892.
29. M Schatz and MP Dombrowski. Asthma in pregnancy. N Engl J Med 2009; 360:1862.
30. NA Hodyl et al. Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroid use for asthma during pregnancy. Am J Respir Crit Care Med 2011; 183:716.
31. L Blais et al. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 2009; 124:1229.
32. M Tegethoff et al. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study. Am J Respir Crit Care Med 2012; 185:557.
33. LN Bakhireva et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007; 119:618.
34. B Cossette et al. Impact of maternal use of asthma-controller therapy on perinatal outcomes. Thorax 2013; 68:724.
35. RS Zeiger et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365:1990.
36. PG Gibson et al. Asthma in older adults. Lancet 2010; 376:803.
37. CE Reed. Asthma in the elderly: diagnosis and management. J Allergy Clin Immunol 2010; 126:681.
38. NA Hanania et al. Asthma in the elderly: Current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol 2011; 128:S4.
39. M Cazzola et al. Asthma and comorbid medical illness. Eur Respir J 2011; 38:42.
40. J Bousquet et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86:8.
41. TO Kiljander et al. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181:1042.
42. American Lung Association Asthma Clinical Research Centers et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360:1487.
43. JT Holbrook et al. Lansoprazole for children with poorly controlled asthma. JAMA 2012; 307:373.
44. E Forno et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol 2011; 127:741.
45. AE Dixon et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128:508.
46. A Qaseem et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and the European Respiratory Society. Ann Intern Med 2011; 155:179.
47. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Updated 2013. Available at www.goldcopd.com. Accessed July 17, 2013.
48. Drugs for tobacco dependence. Treat Guidel Med Lett 2008; 6:61.
49. RS McIntyre. Varenicline and suicidality: a new era in medication safety surveillance. Expert Opin Drug Saf 2008; 7:511.
50. R Strassmann et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009; 34:634.
51. GJ Rodrigo et al. Safety of long-acting ß-agonists in stable COPD. A systematic review. Chest 2008; 133:1079.
52. Indacaterol (Arcapta Neohaler) for COPD. Med Lett Drugs Ther 2012; 54:33.
53. DP Tashkin et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.
54. M Decramer et. al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374:1171.
55. TM Michele. The safety of tiotropium – the FDA's conclusions. N Engl J Med 2010; 363:1097.
56. Tiotropium (Spiriva) for COPD. Med Lett Drugs Ther 2004; 46:41.
57. JE Frampton. Aclidinium in chronic obstructive pulmonary disease. Drugs 2012; 72: 1999.
58. EM Kerwin et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9:90.
59. PW Jones et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40:830.
60. Aclidinium bromide (Tudorza Pressair) for COPD. Med Lett Drugs Ther 2012; 54:99.
61. A Gershon et al. Comparison of inhaled long-acting ß-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease. A cohort study. Ann Intern Med 2011; 154; 583.
62. C Vogelmeier et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093.
63. JA Wedzicha. Choice of bronchodilator therapy for patients with COPD. N Engl J Med 2011; 364: 1167.
64. A Gershon et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013; 173:1175.
65. DP Tashkin et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6:17.
66. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
67. FJ Martinez et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 2013; 107:550.
68. PM Calverley et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med 2007; 356:775.
69. IA Yang et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (2): CD002991.
70. Safety of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). Med Lett Drugs Ther 2010; 52:41.
71. T Welte et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:741.
72. D Singh et al. Superiority of "triple" therapy with salmeterol/fluticasone proprionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63:592.
73. NA Hanania et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012; 106:91.
74. TA Lee et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169:1403.
75. JM Michalski et al. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 2012; 91:134.
76. Roflumilast (Daliresp) for COPD. Med Lett Drugs Ther 2011; 53:59.
77. PM Calverley et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two ransomised clinical trials. Lancet 2009; 374:685.
78. RK Albert et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689.
79. JK Stoller et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. CHEST 2010; 138:179.
80. MB Drummond and RAWise. Oxygen therapy in COPD: What do we know? Am J Respir Crit Care Med 2007; 176:321.
81. Adult immunizations. Treat Guidel Med Lett 2011; 9:75.
82. R Casaburi and R ZuWallack. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009; 360:1329.
83. JD Leuppi et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA 2013; 309:2223.
